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Accepted 14 June 2014Objective. In this report we show that the adipocytokine leptin directly modulates
autophagy in human CD4+CD25− conventional (Tconv) T cells.
Results. In vitro treatment with recombinant human leptin determined an inhibition of
autophagy during T cell receptor (TCR) stimulation, and this phenomenonwas dose- and time-
dependent. The eventswere secondary to theactivation of themammalian-target of rapamycin
(mTOR)-pathway induced by leptin, as testified by its reversion induced by mTOR inhibition
with rapamycin. At molecular level these phenomena associated with Bcl-2 up-regulation and
its interaction with Beclin-1, whose complex exerts a negative effect on autophagy.
Materials/methods. The impact of leptin on autophagy of Tconv cells was determined at
biochemical level by western blotting and by flow cytometry; the interaction between BCL-2
and Beclin-1 by co-immunoprecipitation assays.
Conclusions. Our results, suggest that in unconditioned, freshly-isolated human Tconv
cells, autophagy and proliferation are controlled by leptin during TCR-engagement, and that
both phenomena occur alternatively indicating a balance between these processes during
immune activation.







Leptin is a 16 kD adipocyte-derived cytokine that regulates
neuroendocrine functions and controls food intake, energyof rapamycin; TCR, T cel
onventional.




y Elsevier Inc. This is aexpenditure, glucose and fat metabolisms [1]. It mediates its
functions through the long form of the leptin receptor (LepRb)
which is part of the class I cytokine receptors, expressed at
different levels also on innate and adaptive immune cellsl receptor; hLepRb, human leptin receptor-b; LC3-II, microtubule
rsità di Salerno, Baronissi Campus, 84081 Baronissi, Salerno, Italy.
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respectively [2]. In this context, it has been previously
suggested that leptin represents an important link among
nutritional status, metabolism, and immune responses [3,4],
indeed it signals to CD4+ T cells that sufficient amount of
energy is stored as fat to support the increased energy
demand during immune responses against pathogens [5].
Also, leptin shows differential effects on several T cell
subpopulations [6,7] through the activation of themammalian
target of rapamycin (mTOR) pathway [7–9]. mTOR is a
molecular sensor of cellular nutritional status and integrates
signals from the environment to the nucleus for the regulation
of cell metabolism, proliferation, survival and autophagy [10].
mTOR plays a negative role on cellular autophagy [11–14]:
autophagy, from the Greek words, auto “self” and phagein “to
eat”, is the basic catabolic mechanism that involves cell
degradation of unnecessary or dysfunctional cellular compo-
nents through the actions of lysosomes. The breakdown of
cellular components can ensure cell survival during reduced
energy availability (ie. starvation) by maintaining cellular
energy levels [15]. During this process, targeted cytoplasmic
constituents are isolated from the rest of the cell within the
autophagosomes, which are then fused with lysosomes and
degraded or recycled. The molecular mechanism by which
mTOR inhibits autophagy is not completely understood. Over
the past few years, autophagy has been considered as a
process that provides a survival advantage to cells undergoing
nutrient deprivation or other stresses [13–15]. Indeed genetic
or pharmacological alterations in autophagy impair cell
survival rate or cell metabolism, thereby affecting tissue
homeostasis. In the context of the immune system, recent
papers have shown that autophagy may be also linked to
apoptosis [16–18] andmight play different roles in lymphocyte
development [19–21] and function, bymaintaining the normal
number of B, CD4+, CD8+ T cells [22,23] and controlling T cells
activation [18], thymic selection [24] and antigen presentation
[25]. These data indicate that autophagy plays a role in
switching the cell fate toward differentiation or specific
functional commitments, such as T cell polarization, suggest-
ing that metabolic state (through leptin) might influence this
process. Moreover, leptin has been demonstrated to exert
opposite effects on human regulatory CD4+CD25+ (Treg) and
conventional CD4+CD25− (Tconv) T cells: indeed it inhibits
Treg cell proliferation [6], on the one side, whereas it enhances
Tconv proliferation, on the other [7]. These effects on both
cellular subsets were induced by mTOR activation [7,8].
Particularly, on Tconv cells the enhancement in their prolif-
eration associated with inflammatory cytokine secretion,
whereas leptin neutralization determined the inhibition of
their responses, thus suggesting a key role of this adipocyto-
kine in Tconv cells homeostasis and function and in
pathogenesis of several inflammatory and autoimmune
disease [26]. Levels of leptin are, in fact, typically low during
infection and high in autoimmune disorders, both systemi-
cally and at the site of inflammation (ie. multiple sclerosis
(MS), systemic lupus erythematosus (SLE), rheumatoid arthri-
tis (RA)) [26,27]. In this context, this report investigates the role
of leptin, considered as a “dominant” peripheral signal of fuel
availability, on the modulation of the autophagic process in
the context of human Tconv cells biology.2. Materials and methods
2.1. Cell cultures, purification and proliferation assays
The leptin-dependent BAF/3-LepRb+ cell line, stably
transfected with the long form of human leptin receptor
was kindly provided by Prof. Arieh Gertler from the Hebrew
University, Rehovot, Israel. In brief, BAF/3-hLepRb+ cells
were cultured in RPMI-1640 medium in the presence of
human leptin (10 ng/mL), supplemented with 10%
FCS, 2 mmol/L L-glutamine, 100 units/mL penicillin, and
100 μg/mL streptomycin (Life Technologies, Carlsbad, CA).
Cells were cultured at 37 °C in 100% humidity and 5% CO2.
To evaluate the leptin effects on autophagy, in all experi-
ments, BAF/3-hLepRb+ cells (1–2 × 106 cells/well) were leptin
deprived for 12 h and left in low serum (2% FCS). The day
after they were acutely stimulated with recombinant
human leptin (100 ng/mL) (R&D Systems, Minneapolis,
MN) at times shown in figures.
Human CD4+CD25− Tconv cells were purified from PBMCs
from buffy coats of human healthy donors by either magnetic
cell separation with the Dynabeads Treg Cell Kit (Invitrogen)
or by FACS sorting (MoFlo, Dako-Beckman-Coulter), and Tconv
cells purity was always between 95 and 98%. The study was
approved by the Federico II Ethics Review Board and donors
gave informed written consent for the blood donation. Cells
(1–2 × 106 cells/well) werewashed extensively with serum free
culture medium, left in low serum [2% AB human serum
(Invitrogen)] for 2 h at 37 °C in presence of lysosomal protease
inhibitor [NH4Cl (20 mmol/L) and leupeptin (100 μmol/L)
(Sigma)], and after were washed and stimulated or not with
recombinant human leptin (100–200 ng/mL) (R&D Systems,
Minneapolis, MN) plus anti-CD3/CD28 mAbs coated beads
(0.2 beads/cell, Invitrogen) for 2 h at 37 °C. For proliferation
assays, Tconv cells were stimulated or not with human leptin
(200 ng/mL) and human leptin-neutralizing mAb (R&D Sys-
tems, Minneapolis, MN), used at a final concentration of 0.25
to 25 mg/mL. For transient mTOR inhibition, either BAF/3-
hLepRb+ or Tconv cells were pre-treated for 1 h with
rapamycin (Sigma-Aldrich) at final concentration of
100 nmol/L. Cells were stimulated for 3 days, labeled with
[3H]thymidine (0.5 mCi/well) (Amersham-Pharmacia Biotech,
Cologno Monzese, Italy) for the last 16 h of culture, and
harvested after 12 h (Tomtec). Radioactivity was measured
with a β-cell-plate scintillation counter (Wallac, Gaithersburg,
MD). For mouse studies, 8–10-wk-old C57BL/6J (B6) wild-type
(WT), and leptin–deficient mice (C57BL/6J-ob/ob) were pur-
chased from Charles River Laboratories (Calco, Italy). The
study was approved by the Ethical Veterinary Board of the
Federico II University.
For biochemical analyses on mouse cells, 1–2 × 106 Tconv
cells (isolated by negative selection using the Miltenyi Biotec
Treg Cell Isolation kit and an AutoMACS cell separator, cell
purity >95%), were obtained from the splenocytes of each
group ofWT or C57BL/6J-ob/obmice and left for 12 h in 2% FCS,
2 mmol/L L-glutamine, 100 units/mL penicillin, and 100 μg/mL
streptomycin (Life Technologies, Carlsbad, CA). The day after,
cells were stimulated for 2 h with mouse recombinant leptin
(200 ng/mL) (R&D Systems, Minneapolis, MN).
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BAF/3-hLepRb+ cells, starved as previously described, were
incubated with 0.05 mmol/L monodansyl-cadaverine (MDC)
(Sigma Aldrich) at 37 °C for 10 min in presence or absence of
leptin and analyzed by FACS (FACS-Canto Becton-Dickinson,
San Diego, CA) and analyses were performed by Flow-Jo
software (Tree Star, Ashland, OR).
2.3. Immunoblotting analyses
Total cell lysates were prepared by dissolving the cell pellet in
cold radioimmune precipitation assay buffer RIPA (50 mmol/L
Tris–HCl, pH 7.5, 150 mmol/L NaCl, 1% Nonidet P-40, 0.5%
deoxycholate, 0.1% SDS and a mixture of protease and
phosphatase inhibitors) for 15 min at 4 °C. The lysate was
centrifuged (10,000 × g for 10 min); the supernatant was col-
lected, quantized and resuspended in electrophoresis sample
buffer, heated to 95 °C for 5 min and resolved on a SDS 15%
polyacrylamide gel. Western blot with specific antibodies were
used according to the protocol provided by the supplier. For all
western blot shown 20 μg of total protein extracts was loaded;
antibodies used were: anti-LC3 A/B, anti-phospho-STAT3 and
anti-STAT3, anti-phospho-S6, anti-S6, (Cell Signaling Technol-
ogy, Beverly, MA); anti-ERK1/2, anti-phospho-ERK1/2, anti-Bcl-2
and anti-actin (all from Santa Cruz Biotechnology, Santa Cruz,
CA). Lysosomal protease inhibitors NH4Cl plus leupeptin
(Sigma) were used, at final concentration of 20 mmol/L and
100 μmol/L respectively, to better preserve theamountof LC3-II.
2.4. Co-immunoprecipitation
BAF/3-hLepRb+ cells (14 × 107) were lysed in HEMG buffer
(25 mmol/L HEPES (pH 8.0), 100 mmol/L NaCl, 0.5% Nonidet
P-40, 0.1 mmol/L EDTA, 10% glycerol) plus protease and
phosphatase inhibitors to detect endogenous Beclin–Bcl-2
complex. Equal amounts of protein (400 μg per experimental
point) were incubated with a mouse monoclonal anti-Bcl-2 Ab
(Santa Cruz Biotechnology) and amouse pre-immune IgG at the
sameconcentrationovernight at 4 °C. The conditionsusedwere
in according to the protocol provided by the supplier. Eluates
were resolved on a SDS 12% polyacrylamide gel and detected by
WB with a rabbit anti-Beclin-1 Ab (Cell Signaling) and a rabbit
anti-Bcl-2 Ab (Santa Cruz Biotechnology).
2.5. Statistical analysis
We used non-parametric Mann–Whitney U tests. The statis-
tical software used was GraphPad InStat3 version 4.0. Results
are expressed as mean ± S.E.M. P values <0.05 were consid-
ered statistically significant.3. Results
3.1. Human leptin modulates proliferation and autophagy
of BAF/3-hLepRb+ cells
To assess the role of leptin in the modulation of the
autophagic process we firstly utilized an immortalized cellline, BAF3, stably transfected with the full-length human
leptin receptor (hLepRb) (see Methods for details) whose
proliferation in vitro has been previously shown to be totally
dependent on presence of leptin in culture medium. Firstly,
we performed human recombinant leptin dose responses in
vitro by measuring proliferation of the BAF/3-hLepRb+ cell line
(Fig. 1A). Human leptin induced a dose-dependent prolifera-
tion of BAF/3-hLepRb+ cells through the engagement of LepRb
since the phenomenon was completely abrogated by leptin
neutralization with an anti-leptin mAb (Fig. 1A). These events
were secondary to leptin-LepRb-STAT3 activation as sug-
gested by increase in the P-STAT3 levels (Fig. 1B left). Indeed,
in time course experiments, P-STAT3 revealed an oscillatory
trend reaching a maximal activation at 30′ rapidly subsiding
after 60′–120′. To evaluate whether leptin plays also a role on
mTOR regulation, we analyzed P-STAT3 levels in presence of
rapamycin, a potent mTOR inhibitor. Transient inhibition of
mTOR (1 h of rapamycin pre-treatment) significantly reduced
the amount of P-STAT3 (Fig. 1B right); also, leptin treatment
after rapamycin pretreatment, was able to restore P-STAT3
levels albeit to a lower extent at 30′ (Fig. 1B right). To get
further insights into mTOR pathways activity, we analyzed S6
phosphorylation, a downstream target of mTOR activity.
Phospho-S6 was rapidly induced by leptin treatment and
significantly inhibited by rapamycin pre-treatment. These
phenomena were partly reversed by leptin (Fig. 1C right).
To evaluate the effect of leptin on the autophagic
machinery, we used two different approaches: 1) flow
cytometry analysis of the autofluorescent drug monodansyl-
cadaverine (MDC), which is a specific autophagolysosome
marker; 2) western blotting analysis of the microtubule
associated protein light chain 3-II (LC3-II) protein, a well
known marker of autophagy, by analyzing the conversion of
LC3-I in LC3-II (autophagic flux) as LC3-II/LC3-I ratio. Leptin
treatment significantly reduced the amount of MDC (Fig. 1D)
and of LC3-II/LC3-I ratio (Fig. 1E), this inhibitory effect on
autophagy wasmaximal at 60–120 min (Fig. 1E left). Finally, to
evaluate whether leptin effects on autophagy could be
mediated by mTOR pathway modulation, we studied this
phenomenon in presence of rapamycin (Fig. 1E right). As
expected, rapamycin alone increased autophagy and the
phenomenon was reversed by leptin (Fig. 1E right). To rule
out that LC3-II/LC3-I reduction was induced by leptin and not
due to lysosomal proteases degradation, we tested the
autophagic flux in presence or absence of lysosomal protease
inhibitors (NH4Cl/leupeptin) (Supplemental Fig. 1), confirming
that the observed phenomenon was specifically reduced
by leptin.
3.2. TCR and hLepRb modulate autophagy in human
Tconv cells
To study the possible link between proliferation and
autophagy in normal human T cells, we studied the autoph-
agic flux also in highly purified, leptin-stimulated CD4+CD25−
Tconv cells. We firstly, tested the capacity of leptin to affect
Tconv cell proliferation in the presence or absence of mTOR
inhibition (Fig. 2A). Indeed, we confirmed that leptin neutral-
ization in the culture medium was able to inhibit Tconv
proliferation (Fig. 2A): the phenomenon was specific since it
Leptin






























































































































Fig. 1 – Leptin modulates autophagy via mTOR in BAF/3-hLepRb+ cells.3H-thymidine incorporation in BAF/3-hLepRb+ cells
stimulated with human leptin (0.01–10 ng/mL) in a dose response assay (A). Densitometric analysis of P-STAT3/STAT3 (B) and
P-S6/S6 (C). Leptin (left panel) plus rapamycin (right panel) were used at 100 ng/mL and 100 nmol/L respectively at times shown
in figures. BAF/3-hLepRb+ cells cultured in the presence or absence of leptin, were stained withmonodansyl-cadaverine (MDC)
and analyzed by flow cytometry (D). Autophagy levels were measured also by western blotting analysis and calculated as the
ratio LC3-II/LC3-I. LC3-II was also normalized against actin. BAF/3-hLepRb+ cells were stimulated with leptin (left panel) plus
rapamycin (right panel) at the same times and concentrations above described (E). The values shown represent themean ± S.E.
M. of at least three experiments one representative out of three independent experiments. ⁎p < 0.05, ⁎⁎p < 0.03.
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presence of anti-leptin neutralizingmAb. Rapamycin behaved
similarly to the anti-leptin neutralizingmAb, since it inhibited
Tconv cells proliferation and this inhibition was partly
reversed by leptin. These experiments suggest that leptin
supports T cell proliferation upon TCR-stimulation, and that
these phenomena occurred via mTOR activation, since
rapamycin was able to reduce T cell proliferation, phenome-
non which was reversible in vitro by leptin treatment. Parallel
biochemical analyses revealed that Tconv lymphocytes, in thepresence of increasing leptin concentrations, reduced autoph-
agy (Fig. 2B). Leptin alone on purified, not-stimulated Tconv
cells was not able to reduce autophagy in a dose dependent
manner; this phenomenonwas strongly induced by CD3/CD28
stimulation alone, and addition of leptin during TCR stimu-
lation enhanced this phenomenon in a dose dependent
manner (Fig. 2B). In these experimental conditions, leptin
induced S6-phosphorylation, and this increase was main-
tained also during CD3/CD28 stimulation (Fig. 2C), suggesting
an additive effect on the mTOR pathway induced by parallel
1276 M E T A B O L I S M C L I N I C A L A N D E X P E R I M E N T A L 6 3 ( 2 0 1 4 ) 1 2 7 2 – 1 2 7 9LepRb and TCR stimulation (Fig. 2C). Parallel, P-ERK1/2
analyses revealed little but significant effect of leptin on ERK1/
2 phosphorylationwhichwas not further potentiated after CD3/
CD28 engagement (Supplemental Fig. 2A). In this context we
also repeated these experiments before and after rapamycin
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Fig. 2 – Leptin modulates autophagy viamTOR in CD4+ CD25−
Tconv cells.3H-thymidine incorporation in human Tconv cells
stimulated or not with leptin, anti-leptin neutralizing mAb or
anti-CD3/CD28 beads (0.2 beads/cell), pretreated or not with
rapamycin (60′) (see Methods for details) (A). Densitometric
analysis of LC3-II/LC3-I (B), P-S6/S6 (C) in human Tconv cells
stimulated for 120′ with increasing human leptin concentra-
tions (100–200 ng/mL) plus anti-CD3/CD28 (0.2 beads/cell) and
in presence or not of rapamycin (60′ at 100 nmol/L) (D, E).
Densitometric analysis of LC3-II/LC3-I ratio in extract from
Tconv cells of ob/ob and WT mice stimulated or not with
recombinant mouse leptin (200 ng/mL) for 120′ (F). Cells
were incubated with lysosomal protease inhibitors NH4Cl
(20 mmol/L) and leupeptin (100 μmol/L) in all experimental
conditions (see Methods for details). Representative of at least
three independent experiments. Data are shown asmean ± S.
E.M. ⁎p < 0.05, ⁎⁎p < 0.03, ns = not significant.induced by leptin during CD3/CD28 stimulation, and the
capacity of leptin to reverse autophagy induced by mTOR
inhibition (Fig. 2D). These phenomena were accompanied by
leptin induction of mTOR pathway activation as testified by
increased S6-phosphorylation (Fig. 2E) while ERK1/2 phosphor-
ylation was not potentiated by leptin during CD3/CD28 engage-
ment (Supplemental Fig. 2B) thus suggesting a direct and
specific effect of leptin on the autophagic machinery during
TCR engagement in Tconv cells through mTOR activation.
3.3. Leptin regulates autophagy in Tconv cells through
Bcl-2/Beclin-1 interaction
To better understand the link between leptin and autophagy
at molecular level we analyzed also in chronic leptin deficient
mouse models such as the ob/obmice, the levels of autophagy
in isolated Tconv cells before and after leptin treatment in vitro
and compared themwith wild-type (WT) animals (Fig. 2F). We
confirmed the results obtained in human Tconv cells since
chronic leptin deficiency associated with high levels of
autophagy compared with WT mice; in both animals leptin
treatment significantly reduced autophagy (Fig. 2F).
Since it is well known that leptin is able tomaintain CD4+ T
cell survival in vitro and in vivo by up-regulation of the pro-
survival/anti-apoptotic gene Bcl-2 [9], we confirmed these
results in our experimental conditions by assessing Bcl-2
levels in BAF/3-hLepRb+ and human Tconv (Fig. 3A and B).
This effect on Bcl-2 was regulated by PI3K-mTOR axis, as
either Ly294002 (a PI3K-inhibitor) or rapamycin pre-treatment
reduced Bcl-2 levels; these phenomena were both partly
reversible upon leptin treatment (Fig. 3A and B).
To get further insights into the molecular machinery
controlled by leptin in the context of autophagy, we analyzed
the interaction between the anti-autophagy Bcl-2 protein and
Beclin-1, a key element of the autophagic cascade [28–30]. Of
note, in our experimental conditions, we found that Bcl-2
co-immunoprecipitated with Beclin-1, thus suggesting a
physical interaction between the anti-autophagy Bcl-2 and
Beclin-1 (Fig. 3C left). These findings suggest that leptin
inhibits autophagy by favoring the Bcl-2 up-regulation and
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Fig. 3 – Leptin controls autophagy via a physical interaction of Bcl-2 with Beclin-1.Densitometric analysis of Bcl-2/Actin in
human CD4+CD25− Tconv cells (B) and in BAF/3-hLepRb+ cells (C) after leptin stimulation (120′ at 200 and 100 ng/mL
respectively) in presence and absence of rapamycin (100 nmol/L) (B) or Ly294002 (2.5 μmol/L) (C). Densitometric analyses
represent the mean ± S.E.M. of at least three experiments one representative out of three independent experiments. ⁎p < 0.05,
⁎⁎p < 0.03, ns = not significant. Co-immunoprecipitation of Beclin-1 with Bcl-2 in BAF/3-hLepRb+ cells in presence and absence
of leptin (200 ng/mL) (D), one representative experiment out of two replicates (IP, immunoprecipitate; WB, western blot; WCL,
whole cell lysates).
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In this report we show that leptin, through mTOR, regulates
autophagy and this effect occurs both in a leptin-dependent
system such as the BAF/3-hLepRb+ transfectants and in
human primary CD4+CD25− Tconv cells. It is well corroborated
that leptin plays pleiotropic functions on the immune system
by signaling that sufficient amount of energy is stored as fat in
body reserves [31]. Since leptin activates mTOR [7–9] (which
has key functions in controlling the autophagic process) we
asked whether this cytokine-like hormone could affect this
process. Autophagy is involved in the development and/or
homeostasis of several immune cell populations [32]. Indeed
the knockout of different autophagy genes in specific lympho-
cyte populations in mice has shown a crucial role for
autophagy proteins in the development and maintenance
of normal numbers of B cells, CD4+ T cells, CD8+ T cells, in
antigen presentation and in the elimination of autoreactive
T cells in the thymus [19–25]. Moreover, both autophagy and
leptin have been suggested to play a key role in the
modulation of the onset and outcome of several autoim-
mune diseases [33]. Recent evidence suggests that autoph-
agy, through the modulation of antigen presentation, is
involved in presentation of citrullinate peptide, a hallmark
of RA [34], and in the activation of CD8+ T cells for the
elimination of microorganisms during infection [35]. Inter-estingly, it has been shown that autophagy is implicated
also in the survival of autoreactive B cells in SLE [36] and
genome-wide association studies have shown association
between single nucleotide polymorphism (SNP) in some
autophagy related genes (ATG) with susceptibility to SLE
[37], RA [38] and Crohn's disease [39].
Recent evidence indicates that leptin also promotes
autoimmune disorders by enhancing pro-inflammatory
cytokine secretion and immune responses [40]. In several
autoimmune diseases, such as RA high serum leptin levels
have been found [41,42], while, on the contrary, fasting,
which associates with a marked decrease in serum leptin
amount and a shift toward Th2-type cytokine secretion,
improves clinical disease activity in RA patients [43].
Furthermore leptin has been shown to promote Th17
responses in normal human CD4+ T cells and in (NZB X
NZW) F1 lupus-prone mice, by inducing RORγ transcrip-
tion, whereas, on the contrary, its neutralization in those
autoimmune-prone mice inhibits Th17 responses [44].
Leptin has also been linked to spontaneous autoimmune
disease such as type 1 diabetes (T1D) in the non-obese
diabetic (NOD) mice [45] and in the induction and
progression of EAE, a mouse model of MS [46,47]. Moreover,
leptin can negatively modulate the expansion of human
Treg cells [6] a cellular subset, which suppress autoreactive
response mediated by Tconv cells thus suggesting a central
role exerted by leptin in the pathogenesis of several
1278 M E T A B O L I S M C L I N I C A L A N D E X P E R I M E N T A L 6 3 ( 2 0 1 4 ) 1 2 7 2 – 1 2 7 9autoimmune diseases. Leptin influences Tconv cell func-
tions through mTOR activation thus causing a defined
cellular, biochemical and transcriptional modification that
determines the outcome of their responses, both in vitro
and in vivo and also confirming that this pathway might
integrate cellular energy status with metabolic-related
signaling in Treg/Tconv that use this information to
control immune tolerance [7].
We observed a distinct capacity of leptin to inhibit the
autophagic process in human Tconv cells. This phenomenon
was rapid and early, sustained by the TCR engagement, which
was able alone to inhibit autophagy at maximal level (Fig. 2B).
The capacity of leptin to reduce autophagy was also confirmed
in theTconv cells fromthe leptin-deficient ob/obmouse (Fig. 2F),
since these cells showed a high level of autophagy when
compared with WT counterparts (Fig. 2F). In this report we
further a possible molecular mechanism accounting for the
capacity of leptin toactivate theanti-apoptotic geneBcl-2which
in turn is able to physically interact and subtract Beclin-1 from
the autophagic cascade (Fig. 3C). These data are in agreement
with reports showing in vivo that leptin activates pro-survival
pathways, including Bcl-2 [9], which in turn has determinant
activities also on the autophagic machinery via its physical
interaction with Beclin-1 [28].
Finally, our report unveils a novel mechanism of control
exerted by nutritional status and metabolism on Tconv
cells via leptin's control on autophagy. These effects can
partly explain some of the well known anti-inflammatory
activities induced by either nutritional deprivation or
rapamycin treatment both able to significantly reduce
circulating leptin, Tconv cell proliferation and consequent-
ly systemic inflammation.Author contribution
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